Acer Therapeutics Inc. Common Stock (DE)
ACER
ACER: Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
moreShow ACER Financials
Recent trades of ACER by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ACER's directors and management
Government lobbying spending instances
-
$20,000 Jul 18, 2023 Issue: Pharmacy
-
$20,000 Apr 19, 2023 Issue: Pharmacy
-
$20,000 Jan 18, 2023 Issue: Pharmacy
-
$20,000 Oct 19, 2022 Issue: Pharmacy
-
$20,000 Jul 19, 2022 Issue: Pharmacy
-
$20,000 Apr 19, 2022 Issue: Pharmacy
-
$20,000 Jan 19, 2022 Issue: Pharmacy
-
$20,000 Oct 20, 2021 Issue: Pharmacy
-
$20,000 Jul 20, 2021 Issue: Pharmacy
-
$20,000 Apr 20, 2021 Issue: Pharmacy
-
$30,000 Jan 20, 2021 Issue: Pharmacy
-
$30,000 Oct 16, 2020 Issue: Pharmacy
-
$10,000 Jul 16, 2020 Issue: Pharmacy
-
$10,000 Apr 20, 2020 Issue: Pharmacy
-
$10,000 Jan 17, 2020 Issue: Pharmacy
-
$20,000 Oct 18, 2019 Issue: Pharmacy
-
$20,000 Jul 19, 2019 Issue: Pharmacy
-
$10,000 Apr 21, 2019 Issue: Pharmacy
New patents grants
-
Patent Title: Palatable compositions including sodium phenylbutyrate and uses thereof Sep. 06, 2022
-
Patent Title: Methods of treating urea cycle disorders and maple syrup urine disease Dec. 21, 2021
-
Patent Title: Palatable compositions including sodium phenylbutyrate and uses thereof Oct. 26, 2021
Federal grants, loans, and purchases
Followers on ACER's company Twitter account
Number of mentions of ACER in WallStreetBets Daily Discussion
Recent insights relating to ACER
Recent picks made for ACER stock on CNBC
ETFs with the largest estimated holdings in ACER
Flights by private jets registered to ACER